← Eichor
Condition: Mash Metabolic Dysfunction Associated Steatohepatitis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mash Metabolic Dysfunction Associated Steatohepatitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Phase 2 · 5 location(s) · Regeneron Pharmaceuticals · NCT07527910Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813508Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NA · 2 location(s) · Pichamol Jirapinyo, MD, MPH · NCT06138821High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
Phase N/A · 1 location(s) · Shanghai East Hospital · NCT07463287Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Phase 2 · 17 location(s) · Madrigal Pharmaceuticals, Inc. · NCT07335601A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic
Phase 2 · 31 location(s) · Rivus Pharmaceuticals, Inc. · NCT07491458Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
NA · 3 location(s) · E-Scopics · NCT06661655Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
NA · 1 location(s) · Hospices Civils de Lyon · NCT07313007A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Phase 2 · 17 location(s) · Shanghai Jiao Tong University School of Medicine · NCT07303803A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or
Phase 3 · 53 location(s) · GlaxoSmithKline · NCT07221188LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C
Phase 3 · 444 location(s) · Boehringer Ingelheim · NCT06632457A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 2 · 1 location(s) · The United Bio-Technology (Hengqin) Co., Ltd. · NCT07145151A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfu
Phase 1 · 1 location(s) · Boehringer Ingelheim · NCT06575400A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction
Phase 3 · 356 location(s) · Akero Therapeutics, Inc · NCT06215716Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
Phase N/A · 1 location(s) · Danderyd Hospital · NCT07476703Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Phase 1 · 1 location(s) · Corcept Therapeutics · NCT06947304Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study
Phase N/A · 2 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT07188220Thermoacoustic Method for Estimating Liver Fat Fraction
Phase N/A · 1 location(s) · Endra Lifesciences · NCT07321925A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Phase 3 · 361 location(s) · 89bio, Inc. · NCT06318169Digoxin In NASH (CODIN)
Phase 2 · 2 location(s) · Yale University · NCT06588699Evaluating the Pharmacokinetics and Safety of Miricorilant
Phase 1 · 1 location(s) · Corcept Therapeutics · NCT07553663Resmiterom Efficacy & Safety in Patients With MASH
Phase 4 · 1 location(s) · Nabiqasim Industries (Pvt) Ltd · NCT07249788A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Phase 3 · 91 location(s) · GlaxoSmithKline · NCT07221227A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction-
Phase 2 · 27 location(s) · Boehringer Ingelheim · NCT07325526Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
NA · 1 location(s) · University of California, San Diego · NCT06824974A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Phase 2 · 30 location(s) · GlaxoSmithKline · NCT06920043COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Dis
Phase 1 · 1 location(s) · University of Oxford · NCT06704516Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
Phase N/A · 1 location(s) · Institute of Liver and Biliary Sciences, India · NCT07685353A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or Wit
Phase 1/Phase 2 · 4 location(s) · Regeneron Pharmaceuticals · NCT06836609A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Phase 3 · 323 location(s) · Akero Therapeutics, Inc · NCT06528314
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.